Stockscreener 앱 받기
26.89
6.86%
-1.98
시간 외 거래:
26.92
0.03
+0.11%
전일 마감가:
$28.87
열려 있는:
$28.15
하루 거래량:
1.21M
Relative Volume:
1.21
시가총액:
$2.50B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-7.2091
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
-22.57%
1개월 성능:
-21.05%
6개월 성능:
-49.40%
1년 성능:
-42.36%
1일 변동 폭
$26.48
$28.54
1주일 범위
$26.48
$34.55
52주 변동 폭
$26.48
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
26.89 | 2.50B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-11 | 개시 | TD Cowen | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Peer Perform |
| 2025-01-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq
Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com
(CRNX) Trading Report - news.stocktradersdaily.com
Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia
Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com
Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia
Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com
Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
US Bancorp DE Sells 5,176 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Where are the Opportunities in (CRNX) - Stock Traders Daily
Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews
Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq
Crinetics Awards Major Stock Grants to 17 New Hires Including Executive - Stock Titan
Proficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals - TipRanks
Principal Financial Group Inc. Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharma’s Earnings Call: Progress Amid Challenges - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 6.1% on Better-Than-Expected Earnings - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance UK
Cantor Fitzgerald lifts Crinetics stock target to $100 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year LowHere's What Happened - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Announces Earnings Results - MarketBeat
Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating - TipRanks
Crinetics price target lowered to $91 from $92 at Citizens JMP - TipRanks
Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development - TipRanks
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus.com
Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials - TipRanks
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Crinetics Pharmaceuticals: Financial Results and Future Plans - TipRanks
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Knight Jeff E. | Chief Operating Officer |
Mar 19 '25 |
Sale |
34.20 |
7,162 |
244,964 |
87,491 |
| Betz Stephen F. | Chief Scientific Officer |
Mar 19 '25 |
Sale |
34.20 |
5,770 |
197,353 |
108,588 |
| Struthers Richard Scott | President & CEO |
Mar 19 '25 |
Sale |
34.20 |
17,338 |
593,017 |
329,147 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Option Exercise |
16.89 |
5,000 |
84,450 |
36,748 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
3.01%
자본화:
|
볼륨(24시간):